Drug Profile
PVAC
Alternative Names: PVACLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator SR Pharma
- Class Antipsoriatics; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis; Scleroderma
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 29 Dec 2003 Discontinued - Phase-I for Scleroderma in USA (unspecified route)
- 22 Dec 2003 Discontinued - Phase-II for Psoriasis in Brazil (Intradermal)